Liver Cirrhosis Clinical Trial Pipeline Analysis: Emerging Therapies and Key Companies Advancing the Future of Liver Cirrhosis Treatment | DelveInsight

DelveInsight's "Liver Cirrhosis Pipeline Insight, 2026" report provides comprehensive global coverage of the evolving therapeutic landscape for Liver Cirrhosis, highlighting pipeline therapies across different stages of clinical development, key pharmaceutical companies actively advancing innovative treatment approaches, and future opportunities expected to transform the management of this chronic liver disease. The report delivers in-depth insights into disease pathophysiology, pipeline dynamics, therapeutic assessment, market drivers, barriers, and unmet needs shaping the future of the Liver Cirrhosis treatment market.

Key Takeaways from the Liver Cirrhosis Clinical Trial Landscape Report
• DelveInsight's Liver Cirrhosis pipeline report depicts a promising development landscape with multiple therapies being evaluated across Phase I, Phase II, and Phase III stages of clinical development.
• Key Liver Cirrhosis companies actively involved in therapeutic development include Madrigal Pharmaceuticals, Merck Sharp & Dohme LLC, Gwo Xi Stem Cell Applied Technology Co., Ltd., PharmaIN, Boehringer Ingelheim, Zydus Therapeutics Inc., and others.
• Promising Liver Cirrhosis pipeline therapies in development include Resmetirom, Efinopegdutide, GXHPC1, PHIN-214, BI 3802876, Saroglitazar Magnesium, and others.
• The pipeline encompasses a diverse range of mechanisms of action, including THR-β agonists, dual GLP-1/glucagon receptor agonists, stem cell therapies, vasopressin receptor agonists, and peroxisome proliferator-activated receptor (PPAR) agonists.
• The growing focus on disease-modifying therapies aimed at reducing fibrosis, restoring liver function, and preventing disease progression is expected to significantly advance the treatment landscape for patients with liver cirrhosis.

Request a sample and discover the latest advances in Liver Cirrhosis treatment development.
https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Liver Cirrhosis?
Liver Cirrhosis is a late-stage liver disease characterized by the replacement of healthy liver tissue with scar tissue, resulting in permanent liver damage and impaired liver function. The disease develops as a consequence of chronic liver injury and is histologically defined by regenerative nodules surrounded by fibrous bands. Progressive fibrosis eventually leads to portal hypertension and end-stage liver disease.
Activation of hepatic stellate cells plays a central role in the development of liver fibrosis and cirrhosis. The condition is associated with multiple pathological processes involving cytokines, microRNAs, endothelial dysfunction, inflammation, and extracellular matrix accumulation.
According to published research highlighted in the report, approximately 2.05 million new cases of liver cirrhosis were reported globally in 2019, with nearly 1.47 million deaths attributed to the disease, representing an increase of 8.1% compared to 2017.
Common symptoms include fatigue, weakness, jaundice, ascites, lower-extremity edema, appetite loss, weight loss, bleeding tendencies, and hepatic encephalopathy. Major causes include chronic alcohol consumption, hepatitis B and C infections, non-alcoholic fatty liver disease (NAFLD), autoimmune hepatitis, biliary disorders, and genetic conditions such as hemochromatosis and Wilson's disease.

Emerging Liver Cirrhosis Drug Profiles

Resmetirom: Madrigal Pharmaceuticals, Inc.
Resmetirom (Rezdiffra; MGL-3196) is a liver-directed, selective thyroid hormone receptor-beta (THR-β) agonist being developed by Madrigal Pharmaceuticals for the treatment of Liver Cirrhosis associated with non-alcoholic steatohepatitis (NASH). The therapy is currently the most advanced pipeline candidate and is being evaluated in Phase III clinical development.

The ongoing MAESTRO-NASH-OUTCOMES Phase III trial is evaluating Resmetirom in patients with well-compensated NASH cirrhosis. The study is expected to enroll approximately 700 participants and is anticipated to conclude in December 2026.

Results from the Phase III MAESTRO-NAFLD-1 trial demonstrated encouraging efficacy. Patients treated with Resmetirom achieved a mean reduction of 6.7 kPa in liver stiffness measured by vibration-controlled transient elastography (VCTE), representing one of the largest reductions reported in patients with compensated MASH cirrhosis. Approximately 51% of patients achieved at least a 25% reduction in liver stiffness, a clinically meaningful outcome associated with reduced progression to end-stage liver disease. The therapy also demonstrated a favorable safety and tolerability profile.

Efinopegdutide: Merck Sharp & Dohme LLC
Efinopegdutide is a dual GLP-1/glucagon receptor agonist currently being evaluated in Phase II clinical development for Liver Cirrhosis. The therapy is administered subcutaneously and is designed to improve metabolic dysfunction and reduce liver disease progression.

GXHPC1: Gwo Xi Stem Cell Applied Technology Co., Ltd.
GXHPC1 is an investigational stem cell therapy currently being developed in Phase II clinical studies. The therapy is administered intrahepatically and aims to restore liver function through cellular regeneration and tissue repair mechanisms.

PHIN-214: PharmaIN
PHIN-214 is an early-stage investigational therapy currently being evaluated in Phase I clinical development. The therapy is administered subcutaneously and represents a novel therapeutic approach for patients with liver cirrhosis.

Recent Developments in the Liver Cirrhosis Clinical Trial Landscape
• In November 2025, Madrigal Pharmaceuticals announced positive two-year data from the compensated MASH cirrhosis arm of the Phase III MAESTRO-NAFLD-1 trial evaluating Rezdiffra. The findings were presented at the American Association for the Study of Liver Diseases (AASLD) meeting and demonstrated clinically meaningful improvements in liver stiffness among patients with advanced disease.
• In February 2025, Madrigal Pharmaceuticals reported positive two-year results from the open-label compensated MASH cirrhosis cohort of the MAESTRO-NAFLD-1 trial, further supporting the potential role of Resmetirom in advanced liver disease management.
• In June 2024, Lipocine announced Phase II data for LPCN 1148 at the European Association for the Study of the Liver (EASL) Congress. The study demonstrated improvements in sarcopenia and hepatic encephalopathy among patients with cirrhosis following 52 weeks of treatment.
• Continued advances in stem cell therapies, metabolic-targeted treatments, and fibrosis-directed approaches are expected to further strengthen the Liver Cirrhosis pipeline over the coming years.

Scope of the Liver Cirrhosis Pipeline Report
• Coverage: Global
• Therapeutic Assessment by Product Type: Monotherapy and Combination Therapy
• Therapeutic Assessment by Clinical Stage: Phase I, Phase II, Phase III, Preclinical, and Discovery
• Therapeutic Assessment by Route of Administration: Oral, Intravenous, Subcutaneous, Intrahepatic, and Parenteral
• Therapeutic Assessment by Molecule Type: Small Molecules, Recombinant Fusion Proteins, Stem Cell Therapies, and Others
• Key Liver Cirrhosis Companies: Madrigal Pharmaceuticals, Merck Sharp & Dohme LLC, Gwo Xi Stem Cell Applied Technology Co., Ltd., PharmaIN, Boehringer Ingelheim, Zydus Therapeutics Inc., and others
• Key Liver Cirrhosis Pipeline Therapies: Resmetirom, Efinopegdutide, GXHPC1, PHIN-214, BI 3802876, Saroglitazar Magnesium, and others

Dive deep into rich insights on emerging therapies, clinical trial activities, and future treatment opportunities in the Liver Cirrhosis therapeutic landscape. https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Liver Cirrhosis Pipeline Report Introduction
2. Liver Cirrhosis Pipeline Executive Summary
3. Liver Cirrhosis Overview
4. Disease Introduction
5. Signs and Symptoms
6. Causes
7. Pathophysiology
8. Diagnosis
9. Treatment
10. Pipeline Therapeutics
11. Late Stage Products (Phase III)
12. Mid-Stage Products (Phase II/III)
13. Mid-Stage Products (Phase II)
14. Early Stage Products (Phase I)
15. Preclinical Stage Products
16. Therapeutic Assessment
17. Assessment by Product Type
18. Assessment by Route of Administration
19. Assessment by Molecule Type
20. Inactive Products
21. Collaborations Assessment
22. Unmet Needs
23. Market Drivers and Barriers
24. Appendix
25. Report Methodology
26. About DelveInsight

For further information on Liver Cirrhosis pipeline therapeutics, reach out to DelveInsight. https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical and biotechnology companies by providing comprehensive end-to-end solutions to improve business performance. Get hassle-free access to all the healthcare and pharmaceutical market research reports through its subscription-based platform, PharmDelve.

This release was published on openPR.